FDA
11th March 2015

FDA Advisory Panel Recommends Approval of Deoxycholic Acid Injection for Chin Fat Reduction

The sponsor conducted two pivotal phase three trials in the U.S. and Canada, involving 1,022 patients.

FDA Advisory Panel Recommends Approval of Deoxycholic Acid Injection for Chin Fat Reduction

On Monday, the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (17-0) in favor of approval of deoxycholic acid (DCA) subcutaneous injection (Kythera Biopharmaceuticals) for the improvement of the appearance of moderate-to-severe convexity or fullness associated with submental fat. DCA destroys fat cell membranes at the injection site.

The sponsor conducted two pivotal phase three trials in the U.S. and Canada, involving 1,022 patients. The trials were identical in design, and each treatment arm was roughly even in size. Participants received injections “spaced on a 1 cm grid” every 4 weeks, with a maximum of six sessions and no more than 50 injections total, briefing documents noted.

Results in the two trials showed that deoxycholic acid injections were superior to placebo for both the primary (evaluation of the amount of submental fat) and secondary endpoints (magnetic resonance imaging (MRI) scans of the chin and neck and Patient-Reported Submental Fat Impact Scale). Two-grade improvements were seen in 13.4% and 18.6% of participants receiving the active drug in the two studies, versus 0.1% and 3% of those in the placebo groups. Another 70% and 66.5% of subjects showed one-grade improvements, compared with 18.6% and 22.2% in the placebo groups.

Common side effects included bruising, swelling and pain.The MRI scans showed 46% and 40.5% improvement in active-treatment groups compared with 5.2% and 5.3% improvements with placebo.

Despite the positive results, some committee members said they were concerned about the potential for adverse events related to off-label uses of the drug in different locations and amounts.

Robert “Bob” Murphy, Jr., MD, plastic surgeon Lehigh Valley Health Network in Bethlehem, Pa., said he felt the research was “nicely presented and controlled” but worried that some clinicians might use it in the periorbital area where its effects aren’t known.

Chairperson of DODAC, Lynn A. Drake, MD, added that, “if used properly, with appropriate training and appropriate precautions, I think [this product] it’s helpful.”

If it wins final FDA approval, deoxycholic acid will be the first medical treatment for excess chin fat.

The FDA is not obligated to follow the advice of its advisory committee panels, but normally does so.

ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net.

Do you have an upcoming Advisory Committee Meeting?

White Oak Gude

 

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us